Pearson ́s correlation analysis showed no significant association between eGFR and serum sclerostin levels in RCC patients (r = 0.05; p = 0.74) and controls (r = 0.06; p = 0.68) (Fig. 3). This evidence concerns the gene SOST and renal cell carcinoma.